Kazia Therapeutics Files 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Dec 31, 2024 · CIK: 1075880
Sentiment: neutral
Topics: sec-filing, reporting, foreign-private-issuer
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed a routine 6-K, no major news.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on December 31, 2024, reporting for the month of December 2024. The company, based in Sydney, NSW, is a foreign private issuer and files annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates beyond its classification and reporting status.
Why It Matters
This filing indicates Kazia Therapeutics is fulfilling its reporting obligations as a foreign private issuer with the SEC, which is standard procedure for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This is a standard SEC filing for a foreign private issuer, containing no new material information or significant financial events.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- SEC (company) — Securities and Exchange Commission
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report information that Kazia Therapeutics Limited is required to disclose to the public in Australia, as a foreign private issuer.
When was Kazia Therapeutics Limited previously known by another name?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on December 28, 1998.
Where is Kazia Therapeutics Limited's principal executive office located?
Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file its annual reports on Form 20-F or Form 40-F?
Kazia Therapeutics Limited files its annual reports under cover of Form 20-F.
What is the SIC code for Kazia Therapeutics Limited?
The Standard Industrial Classification (SIC) code for Kazia Therapeutics Limited is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 289 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2024-12-31 08:43:25
Filing Documents
- d849763d6k.htm (6-K) — 9KB
- d849763dex991.htm (EX-99.1) — 10KB
- 0001193125-24-287082.txt ( ) — 20KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On December 31, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-276091 and 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated December 31, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 31 December 2024